(HSTM) HealthStream - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42222N1037
HSTM: Software, Training, Education, Talent, Compliance, Scheduling
HealthStream, Inc. (NASDAQ:HSTM) operates in the healthcare technology sector, offering a suite of Software-as-a-Service (SaaS) solutions tailored for healthcare organizations. The company’s platform, hStream, serves as the backbone for a variety of workforce management tools, addressing critical areas such as clinical development, talent management, and compliance. By streamlining these processes, HealthStream helps healthcare providers maintain high standards of care while optimizing operational efficiency.
Since its inception in 1990, HealthStream has established itself as a trusted partner to a diverse range of healthcare entities, including private practices, not-for-profit organizations, and government institutions. Additionally, it serves pharmaceutical and medical device companies, demonstrating its broad appeal across the healthcare ecosystem. This diversified customer base contributes to the companys financial stability and growth prospects.
With a market capitalization of approximately $1.032 billion, HealthStream is a mid-sized player in the health care technology industry. The company’s financial metrics, such as a P/E ratio of 52.23 and a forward P/E of 51.81, indicate a premium valuation, reflecting investor confidence in its growth potential. The price-to-book ratio of 2.90 and price-to-sales ratio of 3.59 suggest that the market values its intangible assets and revenue generation capabilities highly.
Headquartered in Nashville, Tennessee, HealthStream has built a reputation for delivering scalable and reliable solutions in a sector where compliance and credentialing are paramount. Its recurring revenue model, typical of SaaS businesses, provides visibility and predictability, making it an attractive investment opportunity for those seeking exposure to the healthcare technology space. For more information, visit their website at https://www.healthstream.com.
Additional Sources for HSTM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HSTM Stock Overview
Market Cap in USD | 999m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2000-04-05 |
HSTM Stock Ratings
Growth 5y | 48.0% |
Fundamental | 36.3% |
Dividend | 35.5% |
Rel. Strength Industry | 20.9 |
Analysts | 3.67/5 |
Fair Price Momentum | 30.14 USD |
Fair Price DCF | 19.72 USD |
HSTM Dividends
Dividend Yield 12m | 0.38% |
Yield on Cost 5y | 0.50% |
Annual Growth 5y | 5.83% |
Payout Consistency | 37.5% |
HSTM Growth Ratios
Growth Correlation 3m | 42.1% |
Growth Correlation 12m | 92.8% |
Growth Correlation 5y | 56% |
CAGR 5y | 6.34% |
CAGR/Max DD 5y | 0.17 |
Sharpe Ratio 12m | 0.91 |
Alpha | 13.18 |
Beta | 0.70 |
Volatility | 33.59% |
Current Volume | 157.4k |
Average Volume 20d | 170k |
As of March 15, 2025, the stock is trading at USD 31.06 with a total of 157,353 shares traded.
Over the past week, the price has changed by -5.30%, over one month by -8.43%, over three months by -4.07% and over the past year by +21.94%.
Partly, yes. Based on ValueRay Fundamental Analyses, HealthStream (NASDAQ:HSTM) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 36.28 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HSTM as of March 2025 is 30.14. This means that HSTM is currently overvalued and has a potential downside of -2.96%.
HealthStream has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold HSTM.
- Strong Buy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, HSTM HealthStream will be worth about 33.1 in March 2026. The stock is currently trading at 31.06. This means that the stock has a potential upside of +6.6%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 35 | 12.7% |
Analysts Target Price | 32.5 | 4.6% |
ValueRay Target Price | 33.1 | 6.6% |